Full length paperDrug combination in vivo using combination index method: Taxotere and T607 against colon carcinoma HCT-116 xenograft tumor in nude mice
Graphical abstract
Introduction
Drug combination has been widely used in treating various diseases including cancer, acquired immune deficiency syndrome (AIDS), and other diseases involving traditional Chinese medicines [1], [2]. Based on Google, PubMed and Web of Science, the term “drug combination” and “synergistic effect” are listed in >200,000 published scientific papers (Table 1). The large majority of them were carried out in vitro in cellular, cell-free, or molecular levels. The rest were carried out in vivo in animas or in clinical trials. Unfortunately, most of the animal studies in vivo and the phase I clinical trials have been carried out with experimental designs that are impossible to determine synergism or antagonism quantitatively [1], [3].
Among the twelve methods for synergism/antagonism assessments in bio-medical literature during the past eight decades (Table 2), the combination index (CI) method [4], [5] based on the physico-chemical principle of the median-effect equation (MEE) [6] of the mass-action law, with theoretical basis, experimental design, algorithm and computerized simulation, has been most widely used. The CI method quantitatively determines/simulates synergism or antagonism at all doses and all effects levels with small number of data points [1], [7], [8], [9], [10], [11], [12], [13]. So far, the CI method introduced by Chou and Talalay in 1984 [4] has been cited over 4681 times [Google Scholar Citations − Ting-Chao Chou] in over 711 different bio-medical journals (Thomson Reuters Web of Knowledge. http://www.researcherid.com/rid/B-4111-2009).
The drug combinations in vivo using the CI method have been presented in scientific meetings [14], [15] and briefly discussed in the review/commentary articles [8], [10], but have not been discussed in details with stepwise analysis in experimental design, actual data analysis and tactical and practical precautions in a full length paper. Recently, a step-by-step illustrations of drug combination in vitro for anti-tumor fludelone and panaxytriol in MX-1 cells have been published [9]. The present paper is prepared to provide progressively virtual illustration of anti-tumor drug combinations using the combination index method with Taxotere and T607 compound in human colon carcinoma HCT-116 xenograft tumor bearing athymic nude mice. It is intended to serve as a classic model illustration of quantitative analysis of drug interaction dynamics in complex biological systems.
Section snippets
Materials
Taxotere (Docetaxel, TXT) is a synthetic taxoil anticancer compound targeting microtubule polymerization. The T-900607 (T607) is a derivative of 2-fluoro-1-methoxy-4-pentafluorophenylsulfonamidobezene which covalently modifies β-tubulin residue Cys-239 as described previously [16]. T607, distinct from Taxotere, is efficacious in inhibiting the growth of both sensitive and multidrug resistant cancer cells. The Immunodeficient/athymic nude mice, nu/nu (female, 20–23 gm bodyweight), were purchased
Results
The dose-effect relationships for the therapeutic results of T607 (15, 25, 30, and 35 mg/kg, i.v. Q3Dx4, x3, n = 6 mice per dose for 4 doses), and vehicle control (6 mice), against HCT-116 xenograft tumor, total n = 30, beginning Day 14 to Day 41 are shown in Fig. 1. The full detailed numerical recording of tumor size changes is given in Appendix I in Supplementary information. The optimal/maximal therapeutic effect from Day 29 to Day 35 are summarized in Table 6. The average tumor volumes were
Grant support
This study was supported in parts by Aventis Pharmaceuticals, Bridgewater, NJ 08807; Tularik, Inc., South San Francisco, CA 94080; and SKI Institutional Core Fund, Memorial Sloan-Kettering Cancer Center, New York, NY 10065.
References (25)
Combination screening of synthetic drugs and plant derived natural product −potential and challenges for drug development
Synergy
(2014)- et al.
Quantitative analysis of dose—effect relationships: the combined effects of multiple drugs or enzyme inhibitors
Adv. Enzyme Regul.
(1984) Frequently asked questions in drug combinations and the mass-action law-based answers
Synergy
(2014)Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands
J. Theor. Biol.
(1976)Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies
Pharmacol. Rev.
(2006)Drug combination studies and their synergy quantification using the Chou—Talalay method
Cancer Res.
(2010)Quantitation of synergism and antagonism of two or more drugs by computerized analysis
The mass-action law based algorithms for quantitative econo-green bio-research
Integr. Biol.
(2011)- et al.
Synergistic combination of microtubule targeting anticancer fludelone with cytoprotective panaxytriol derived from panax ginseng against MX-1 cells in vitro: experimental design and data analysis using the combination index method
Am. J Cancer Res.
(2016) The mass-action law based algorithm for cost-effective approach for cancer drug discovery and development
Am. J. Cancer. Res.
(2011)
Thioredoxin reductase inhibitor ethaselen increases the drug sensitivity of the colon cancer cell line LoVo towards cisplatin via regulation of G1 phase and reversal of G2/M phase arrest
Invest. New Drugs
Utility of a PI3K/mTOR inhibitor (NVP-BEZ235) for thyroid cancer therapy
PLoS One
Cited by (45)
Acute anti-inflammatory activity of Artemisia campestris and Citrus aurantium: Effects of essential oil combinations
2023, Biocatalysis and Agricultural BiotechnologyAntitumor synergism between PAK4 silencing and immunogenic phototherapy of engineered extracellular vesicles
2023, Acta Pharmaceutica Sinica BBerberine combined with formononetin inhibits migration of nasopharyngeal carcinoma cells through the MAPK/ERK1/2 signaling pathway
2022, Journal of Functional FoodsA targeting mesoporous dopamine nanodrug platform with NIR responsiveness for atherosclerosis improvement
2022, Biomaterials AdvancesEvaluation of synergism in drug combinations and reference models for future orientations in oncology
2022, Current Research in Pharmacology and Drug Discovery
- 1
These authors contribute equally to this work.